Can pharmacokinetics/pharmacodynamics help in optimizing glycopeptide treatments ?

• efficacy (primary end-point)

• prevention of emergence of resistance(secondary but crucial endpoint)

Previous slide

Next slide

Back to first slide

View graphic version